US pharma group Abbott Laboratories has reported a rise in second-quarter sales from its paediatric nutrition division, although the increase was not enough to stem a fall in the first half of the year.
Abbott booked a 1.4% rise in sales to US$987m in the second quarter, helped by continued solid growth in the US and a slower rate of sales decline internationally.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
However, in the first half overall, sales were down 1.3% at $1.91bn. In the first quarter, sales had fallen 4.1% year-on-year.
On a comparable basis, which excludes exchange rates, the Similac brand owner said its first-half sales paediatric nutrition dipped 0.4% year-on-year.
Reflecting on the second quarter, Abbott said its sales growth in the US was above the rate of the growth in the market and was driven by recently launched infant-formula products and by its PediaSure toddler brand. International sales declined 3.7%, with market conditions in China still “challenging”, Abbott said. In the first quarter, Abbott’s international paediatric nutrition sales fell 12.2% year-on-year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
